AMBOS NBGO ASSISTED THROMBOGENICS IN THE WORLDWIDE BIOTECHDEAL OF 2012

The leading Belgian biotech company, Thrombogenics, was honored with the Scrip Award for the "Best Licensing Agreement of 2012" worldwide in the biotech sector. Scrip Awards are the most prestigious international awards in the biotech sector.

ThromboGenics won the award for its deal with Alcon (a subsidiary of Novartis) for the commercialization of its breakthrough ophthalmology drug, Jetrea. Jetrea is the first pharmacological treatment for symptomatic Vitreomacular Adhesion, which is a debilitating eye disease previously only treatable with surgery.

Ambos NBGO, together with in-house counsel Claude Sander, led the negotiating team and acted as counsel for Thrombogenics throughout the deal from the preparation and organization of the bidding process to leading the negotiation and drafting the agreements.

The Ambos NBGO team was led by Kathleen Paisley, co-chair of the IP team, and Roel Nieuwdorp, co-head of the corporate team, both of our Brussels office.

For further information about this transaction, please contact Kathleen Paisley or Roel Nieuwdorp.

Published in: Ambos news